Welcome to Foundation Medicine

Foundation Medicine is intended for UK Healthcare Professionals only. By entering this site you are confirming that you are a UK Healthcare professional.

 

 

 

Our FDA-validated liquid biopsy service for patients with solid tumours.1,2
  

FoundationOne®
Liquid CDx: A next-generation liquid biopsy test

FoundationOne® Liquid CDx is a complementary comprehensive genomic profiling (CGP) service for patients with solid tumours.1,2 FoundationOne® Liquid CDx provides an alternative biopsy service for patients that are not suitable candidates for CGP with FoundationOne® CDx.1,2 Liquid biopsy may provide an opportunity to perform non-invasive, blood-based genomic profiling when:

  • Insufficient or inadequate tissue from a recent biopsy is obtained
  • The tumour is “difficult to reach”
  • Biopsy poses an unacceptable risk to the patient or is contraindicated
  • Progression or recurrence are suspected, repeat biopsy is infeasible or intratumour heterogeneity is suspected4

FoundationOne® Liquid CDx allows for a comprehensive blood-based genomic profiling approach to help support treatment decisions for patients with solid tumours

Clinical uses

Identifies actionable results using peripheral blood from a single draw5‡

FoundationOne® Liquid CDx extends the benefits of CGP to additional clinical situations with a single blood draw.5‡ Liquid biopsies are a non-invasive tool for biomarker testing, which may replace the use of invasive solid tumour biopsies (associated with complications and increased morbidity). As liquid biopsies can be scheduled more frequently during treatment, measurements of tumour burden and early evidence of recurrence or resistance can be identified across several time points. Liquid biopsy may also better reflect the genetic profile of an individual tumour as it provides a full snapshot of information, unlike tissue biopsies which only reflect the specific area of the tumour biopsied.8
Disease progression suspected Treatment draw If tissue insufficient for analysis Liquid biopsy Tissue biopsy feasible Solid tumour patient Single blood
Genes and biomarkers

Analyses 324 genes and reports MSI and bTMB status

FoundationOne® Liquid CDx detects the four main classes of genomic alterations in 324 genes including MSI and bTMB. Also reports Tumour fraction in a single test.1
MSI bTMB and Tumour Fraction Base substitutions Insertions and deletions Copy number alterations Microsatellite instability Rearrangements Analyses 324 known cancer-relevant genes

ctDNA

Examines circulating tumour DNA (ctDNA)

When people have cancer, their blood contains circulating cell-free DNA (cfDNA) released from both healthy tissue and tumour tissue (ctDNA).3 ctDNA is highly fragmented, occurs in very low amounts and varies between tumour type and individual patients.9,10 FoundationOne® Liquid CDx utilises ctDNA extraction to accurately identify unique ctDNA fragments from a single blood draw.‡1,2,5
T umour T i s sue Apop t osis Nec r osis Sec r etion Healt h y T i s sue Main source of cfDNA Apop t osis R elease ctDNA Release cfDNA
In-depth report

Supports clinical decision-making

A clear, in-depth report provides insights on your patient’s genomic profile as well as associated targeted EMA-approved therapies, immunotherapies and relevant clinical trials, approved by the FDA.1
1 Patient and specimen details 2 Summary of all identifed genomic DRUG NAME alterations and biomarkers as well as the number of therapy and clinical trial options 3 Genomic alterations, clinically relevant targeted therapies and clinical trials for each alteration, to help guide your treatment strategy 4 bTMB and MSI status to help inform the use of immunotherapies 5 Therapies ranked alphabetically within NCCN Categories of Preference* 6 Tumour Fraction, the percentage of tumour-derived DNA in the liquid biopsy sample, providing you with a measure of the likelihood of detecting genomic alterations in the liquid biopsy sample Genomic alterations associated with no reportable therapeutic or clinical trial options 8 Mutant allele frequency percentage (MAF%) for base substitutions and insertions and deletions (indels) Historic patient fndings from earlier FoundationOne® tests (depending on local country data protection regulation), allowing you to follow your patient’s genomic profile across their disease journey